logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Minshan Chen

southern medical university - china
H指数:47
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial

局部晚期肝细胞癌在阿替利珠单抗和贝伐珠单抗治疗后行肝切除术与维持治疗的比较（TALENTOP研究）：一项多中心、开放标签、随机、III期临床试验

The Lancet
IF88.5
2026-08-200
PRE
Hui-Chuan Sun; Xiao-Dong Zhu; Feng Shen; Tian-Qiang Song; Xue-Li Bai; Yong-Yi Zeng; Min-Shan Chen; Zhi-Yong Huang; Jian-Qiang Cai; Jie Gao; Ming Kuang; De-Yu Li; Bao-Cai Xing; Xiang-Cheng Li; Tian-Fu Wen; Tao Peng; Yao-Dong Wang; Lian-Xin Liu; Cheng Huang; Ying-Hong Shi
Combining immune checkpoint inhibitors and molecular-targeted agents with hepatic arterial infusion chemotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium tumor thrombus

免疫检查点抑制剂和分子靶向药物联合肝动脉灌注化疗治疗肝癌合并下腔静脉和/或右心房癌栓

HEPATOLOGY INTERNATIONAL
IF6.1
2025-02-110
PRE
Zhong, Suixing; Yi, Junzhe; Chen, Song; Mo, Xiaoyan; Chen, Qifeng; Guo, Wenbo; Jiang, Xiongying; Mu, Luwen; Hu, Yue; Wang, Jiongliang; Song, Yujia; Xu, Jie; Tan, Genjun; Shi, Ming; Chen, Minshan; Lyu, Ning; Zhao, Ming
YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment (vol 23, 186, 2024)

YTHDF2在肿瘤周肝细胞中通过CX3CL1介导的CD8+ T细胞募集介导化疗诱导的抗肿瘤免疫应答（卷23，186，2024）

MOLECULAR CANCER
IF33.9
2025-01-310
OA
Yang, Zhenyun; Wang, Xin; Fu, Yizhen; Wu, Weijie; Hu, Zili; Lin, Qingyang; Peng, Wei; Pan, Yangxun; Wang, Juncheng; Chen, Jinbin; Hu, Dandan; Zhou, Zhongguo; Xu, Li; Zhang, Yaojun; Hou, Jiajie; Chen, Minshan
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
HEPATOLOGY INTERNATIONAL
IF6.1
2024-11-212
OA
Lau, George; Obi, Shuntaro; Zhou, Jian; Tateishi, Ryosuke; Qin, Shukui; Zhao, Haitao; Otsuka, Motoyuki; Ogasawara, Sadahisa; George, Jacob; Chow, Pierce K. H.; Cai, Jianqiang; Shiina, Shuichiro; Kato, Naoya; Yokosuka, Osamu; Oura, Kyoko; Yau, Thomas; Chan, Stephen L.; Kuang, Ming; Ueno, Yoshiyuki; Chen, Minshan; Cheng, Ann-Lii; Cheng, Gregory; Chuang, Wan-Long; Baatarkhuu, Oidov; Bi, Feng; Dan, Yock Young; Gani, Rino A.; Tanaka, Atsushi; Jafri, Wasim; Jia, Ji-Dong; Kao, Jia-Horng; Hasegawa, Kiyoshi; Lau, Patrick; Lee, Jeong Min; Liang, Jun; Liu, Zhenwen; Lu, Yinying; Pan, Hongming; Payawal, Diana A.; Rahman, Salimur; Seong, Jinsil; Shen, Feng; Shiha, Gamal; Song, Tianqiang; Sun, Hui-Chuan; Masaki, Tsutomu; Sirachainan, Ekaphop; Wei, Lai; Yang, Jin Mo; Sallano, Jose D.; Zhang, Yanqiao; Tanwandee, Tawesak; Dokmeci, Akadir; Zheng, Shu-sen; Fan, Jia; Fan, Sheung-Tat; Sarin, Shiv Kumar; Omata, Masao
Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)
LIVER CANCER
IF9.1
2024-10-220
OAAI
Yang, Yu; Sun, Juxian; Cai, Jianqiang; Chen, Minshan; Dai, Chaoliu; Wen, Tianfu; Xia, Jinglin; Ying, Mingang; Zhang, Zhiwei; Zhang, Xuewen; Fang, Chihua; Shen, Feng; An, Ping; Cai, Qingxian; Cao, Jingyu; Zeng, Zhen; Chen, Gang; Chen, Juan; Chen, Ping; Chen, Yongshun; Shan, Yunfeng; Dang, Shuangsuo; Guo, Wei-Xing; He, Jiefeng; Hu, Heping; Huang, Bin; Jia, Weidong; Jiang, Kexiang; Jin, Yan; Jin, Yongdong; Jin, Yun; Li, Gong; Liang, Yun; Liu, Enyu; Liu, Hao; Peng, Wei; Peng, Zhenwei; Peng, Zhiyi; Qian, Yeben; Ren, Wanhua; Shi, Jie; Song, Yusheng; Tao, Min; Tie, Jun; Wan, Xueying; Wang, Bin; Wang, Jin; Wang, Kai; Wang, Kang; Wang, Xin; Wei, Wenjing; Wu, Fei-Xiang; Xiang, Bangde; Xie, Lin; Xu, Jianming; Yan, Mao-Lin; Ye, Yufu; Yue, Jinbo; Zhang, Xiaoxun; Zhang, Yu; Zhang, Aibin; Zhao, Haitao; Zhao, Weifeng; Zheng, Xin; Zhou, Hongkun; Zhou, Huabang; Zhou, Jun; Zhou, Xinmin; Cheng, Shu-Qun; Li, Qiu
The Efficacy and Safety of Bevacizumab Plus Anti-PD-1/PD-L1 Inhibitors in Combination with Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma

贝伐珠单抗联合抗PD-1/PD-L1抑制剂及肝动脉灌注化疗治疗初始不可切除肝细胞癌的疗效与安全性

IMMUNOTARGETS AND THERAPY
IF4.4
2024-10-010
OAAI
Tang, Xiang; Chen, Jinbin; Peng, Wei; Yang, Zhoutian; Hu, Li; Ye, Zhiwei; Fu, Yizhen; Hu, Dandan; Zhou, Zhongguo; Chen, Minshan; Zhang, Yaojun; Wang, Jun-Cheng
Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial

tislelizumab联合lenvatinib作为一线治疗不可切除肝细胞癌患者的疗效和安全性: 一项多中心，单臂，2期试验

BMC MEDICINE
IF8.3
2024-04-2310
OAAI
Xu, Li; Chen, Jinzhang; Liu, Chang; Song, Xiaoling; Zhang, Yanqiao; Zhao, Haitao; Yan, Sheng; Jia, Weidong; Wu, Zheng; Guo, Yabing; Yang, Jiayin; Gong, Wei; Ma, Yue; Yang, Xiaobo; Gao, Zhenzhen; Zhang, Nu; Zheng, Xin; Li, Mengyu; Su, Dan; Chen, Minshan

研究方向

暂未获取到该数据
Y
Yaojun Zhang
H 指数:59论文数:527被引数:1.2万
L
Li Xu
H 指数:47论文数:312被引数:9,032
Z
Zhongguo Zhou
H 指数:26论文数:126被引数:3,770
J
Jinbin Chen
H 指数:26论文数:156被引数:2,113
胡丹丹 封面图
胡丹丹
H 指数:31论文数:221被引数:3,192
J
Juncheng Wang
H 指数:24论文数:123被引数:1,392
Y
Yangxun Pan
H 指数:17论文数:82被引数:806
Y
Yizhen Fu
H 指数:16论文数:52被引数:595
Z
Zili Hu
H 指数:14论文数:47被引数:476
Z
Zhenyun Yang
H 指数:10论文数:29被引数:283